Table 1.
Patient characteristics
| Patient Characteristic | n = 70 |
|---|---|
| Age at repeat surgery (years) | |
| Median, (IQR) | 54.0 (13.9) |
| Mean, (SD) | 53.8 (11.3) |
| Gender | |
| Male, (%) | 31 (44%) |
| Female, (%) | 39 (56%) |
| Molecular Diagnoses | |
| Glioblastoma, IDH-wildtype, WHO grade 4, (%) | 48 (73%) |
| Diffuse astrocytoma, IDH-mutant, (%) | 13 (19%) |
| WHO grade 2 | 6 |
| WHO grade 3 | 3 |
| WHO grade 4 | 4 |
| Oligodendroglioma, IDH-mutant, (%) | 9 (13%) |
| WHO grade 2 | 2 |
| WHO grade 3 | 7 |
| Tumor localizations, (%) | |
| Frontal | 23 (33%) |
| Parietal | 16 (23%) |
| Temporal | 29 (41%) |
| Occipital | 1 (1%) |
| Basal ganglia | 1 (1%) |
| Tumor side, (%) | |
| Right | 35 (50%) |
| Left | 35 (50%) |
| N of previous surgeries | |
| 1 | 50 (71%) |
| 2 | 19 (27%) |
| 3 | 1 (2%) |
| N of previous chemotherapy cycles | |
| None | 2 (3%) |
| 1 | 10 (14%) |
| 2 | 30 (43%) |
| 3 | 23 (33%) |
| 4 or more | 5 (6%) |
| Applied agents | |
| TMZ (temozolomide) | 64 (91%) |
| CCNU (lomustine)/ VP-16 (etoposid) | 48 (69%) |
| BCNU (carmustine) | 1 (1%) |
| PCV (procarbazine, lomustine and vincristine) | 1 (1%) |
| Other modalities | |
| Bevacizumab | 6 (9%) |
| IDH-inhibitors | 2 (3%) |
| Tumor-treating fields | 6 (9%) |
| Tumor vaccines | 2 (3%) |
| Other* | 6 (9%) |
| N of previous radiotherapy courses | |
| 1 | 58 (83%) |
| 2 | 10 (14%) |
| 3 | 2 (3%) |
IQR Inter-quartile range, SD Standard deviation, IDH isocitrate dehydrogenase, WHO World Health Organization. *Therapy agents include Chloroquine, Irinotecan, Palbociclib, Atezolizumab